amgen glp-1 obesity drug market potential Agonists Report 2025-2033, By Product, Molecule, and Geo Glucagon Like Peptide-1 (GLP-1) Agonists
Description
Indian J Gastroenterol
How would benefit, no benefit or harm be measured
This review aims to consolidate available information from case reports and case series regarding rare skin-related adverse outcomes due to GLP-1 use, aiming to provide a comprehensive overview of the presentation, pathogenesis, and management for dermatologists and other clinicians
Do not use natural supplements as an equivalent replacement if you have been recommended pharmaceutical intervention by your doctor
Insulin remains insulin
Under pathological stress, macrophages contribute to inflammatory responses, which drive insulin resistance and T2DM
